EMA cuts new PV teeth on Servier bone drug
This article was originally published in Scrip
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has called for further restrictions on the use of Servier's osteoporosis drug Protelos/Osseor (strontium ranelate) because it may increase the risk of heart problems. It has recommended in-depth evaluation of the product's risks and benefits, and limiting the product's use while this is carried out. Restrictions were placed on the drug last year when other risks were identified.